切换至 "中华医学电子期刊资源库"

中华临床医师杂志(电子版) ›› 2018, Vol. 12 ›› Issue (04) : 204 -211. doi: 10.3877/cma.j.issn.1674-0785.2018.04.004

所属专题: 文献

胃肠道肿瘤

原发性胃淋巴瘤临床病理特征及预后独立危险因素分析
杜楠1, 朱志1,(), 徐惠绵1   
  1. 1. 110001 沈阳,中国医科大学附属第一医院胃肠肿瘤外科
  • 收稿日期:2018-01-20 出版日期:2018-02-15
  • 通信作者: 朱志
  • 基金资助:
    国家自然科学基金(81302129)

Clinicopathological characteristics and prognostic factors of primary gastric lymphoma: a retrospective analysis of 53 cases

Nan Du1, Zhi Zhu1,(), Huimian Xu1   

  1. 1. Department of Gastrointestinal Oncological Surgery, the First Hospital of China Medical University, Shenyang 110000, China
  • Received:2018-01-20 Published:2018-02-15
  • Corresponding author: Zhi Zhu
  • About author:
    Corresponding author: Zhu Zhi, Email:
引用本文:

杜楠, 朱志, 徐惠绵. 原发性胃淋巴瘤临床病理特征及预后独立危险因素分析[J]. 中华临床医师杂志(电子版), 2018, 12(04): 204-211.

Nan Du, Zhi Zhu, Huimian Xu. Clinicopathological characteristics and prognostic factors of primary gastric lymphoma: a retrospective analysis of 53 cases[J]. Chinese Journal of Clinicians(Electronic Edition), 2018, 12(04): 204-211.

目的

分析原发性胃淋巴瘤(PGL)组织分型及围手术期相关因素对预后的影响。

方法

对中国医科大学附属第一医院胃肠肿瘤外科1988年9月至2011年7月期间收治的53例PGL患者的临床病理资料进行回顾性分析,通过Kaplan-Meier生存曲线计算累积生存率,采用Log-rank检验单因素分析和Cox模型多因素分析分析其临床特征及围手术期相关因素对预后的影响,并通过单因素分析法分析不同病理分型,其影响预后相关因素是否存在差异。

结果

53例PGL患者发病年龄21~78岁(平均年龄54岁,中位年龄58岁)。本组病例组织分型:黏膜相关淋巴组织淋巴瘤(MALT)占64.2%(34/53)、弥漫性大B细胞淋巴瘤(DLBCL)22.6%(12/53)。Ann Arbor临床分期:ⅠE期22例(41.5%,22/53)、ⅡE期19例(35.8%,19/53)、ⅢE期1例(1.9%,1/53)、ⅣE期10例(18.9%,10/53)。随访资料完整的53例患者中,1、3、5年生存率分别为81.1%、47.2%、32.1%,总体中位生存期为35个月。单因素分析显示:影响预后的相关因素中性别(P=0.021)、年龄(P=0.028)、肿瘤大小(P=0.004)、手术根治度(P<0.001)、侵犯脏器(P<0.001)、病理组织分型(P=0.006)、Ann Arbor分期(P=0.029)方面差异具有统计学意义;多因素分析显示:手术根治度(OR=3.611)、病变组织分型(OR=1.729)、Ann Arbor分期(OR=1.509)是影响预后的独立因素。影响MALT预后相关因素中性别(P=0.028)、手术根治度(P<0.001)、侵犯脏器(P<0.001)以及Ann Arbor分期(P=0.003)方面差异具有统计学意义。而DLBCL预后与患者胃肠道炎性病变、溃疡等良性疾病史存在相关性(P=0.003)。

结论

肿瘤根治度、侵犯脏器、原发性胃淋巴瘤的组织分型是影响原发性胃淋巴瘤预后的独立因素;患者性别、手术根治度、侵犯脏器、Ann Arbor分期与MALT的预后存在相关性;患者胃肠道疾病史与DLBCL预后存在相关性。

Objective

To analyze the clinical and pathological characteristics and prognostic factors of primary gastric lymphoma.

Methods

The clinical data of 53 patients with primary gastric lymphoma were retrospectively analyzed from September 1988 to July 2011 at the First Hospital of China Medical University. Kaplan-Meier analysis, Log-rank test, Cox regression analysis, and univariate analysis were used to examine whether there was a difference in prognostic factors in different pathological types.

Results

There were 34 males and 19 females, and their age was 21 to 78 years, with an average age of 54 years and a median age of 58 years. There were 4 cases of Hodgkin's lymphoma, 34 cases of mucosa-associated lymphoid tissue (MALT) lymphoma, 12 cases of diffuse large B-cell lymphoma (DCBCL), and 3 cases of lymphoid plasma cell lymphoma. The most common histological type was MALT lymphoma (64.2%), and most patients had Ann Arbor stages IE (41.5%) and IIE (31.7%) diseases. The 1-, 3-, and 5-year survival rates were 81.1%, 47.2%, and 32.1%, respectively. The median overall survival time was 35.0 months. Univariate analysis showed that gender (P=0.021), age (P=0.028), tumor size (P=0.004), tumor resection (P<0.001), organ invasion (P<0.001), histological type (P=0.006), and Ann Arbor stage (P=0.029) were significantly correlated with the prognosis. Multivariable analysis demonstrated that tumor resection (OR=3.611), histological type (OR=1.729), and Ann Arbor stage (OR=1.509) were independent prognostic factors. Moreover, the prognosis of MALT lymphoma was correlated with gender (P=0.028), tumor resection (P<0.001), organ invasion (P<0.001), and Ann Arbor stage (P=0.003). For DLBCL patients, chronic gastric disease were correlated with the prognosis (P=0.003).

Conclusion

Tumor resection, histological type, and Ann Arbor stage are independent prognostic factors. The prognosis of MALT lymphoma correlates with gender, tumor resection, organ invasion, and Ann Arbor stage. For DLBCL lymphoma patients, history of chronic gastric disease correlates with the prognosis.

表1 Ann Arbor胃淋巴瘤临床分期标准
表2 PGL预后影响因素的单因素分析
病例资料 构成比[%(例/例)] 1年生存率(%) 3年生存率(%) 5年生存率(%) χ2 P
性别 ? ? ? ? 5.313 0.021
? 64.2(34/53) 73.5 50.2 28.7 ? ?
? 35.8(19/53) 84.2 73.7 60.8 ? ?
年龄 ? ? ? ? 4.826 0.028
? ≥60岁 45.3(24/53) 66.7 49.2 32.8 ? ?
? <60岁 54.7(29/53) 86.2 67.3 53.5 ? ?
淋巴结检取总数 ? ? ? ? 0.007 0.935
? ≥20个 50.0(23/46) 82.6 59.0 38.2 ? ?
? <20个 50.0(23/46) 82.6 60.6 46.6 ? ?
淋巴结转移 ? ? ? ? 0.350 0.554
? 54.3(25/46) 80.0 54.9 39.9 ? ?
? 45.7(21/46) 81.0 65.4 46.8 ? ?
肿瘤位置 ? ? ? ? 0.084 0.994
? 上、上中 28.3(15/53) 73.3 55.6 33.3 ? ?
? 中、中下 24.5(13/53) 76.5 50.8 38.1 ? ?
? 下部 34.0(18/53) 77.8 60.0 46.7 ? ?
? 全胃 13.2(7/53) 71.4 57.1 42.9 ? ?
既往胃肠道疾病史 ? ? ? ? 0.579 0.447
? 24.5(13/53) 69.2 59.3 47.5 ? ?
? 75.5(40/53) 80.0 55.3 42.3 ? ?
病例资料 构成比[%(例/例)] 1年生存率(%) 3年生存率(%) 5年生存率(%) χ2 P
淋巴管瘤栓 ? ? ? ? 0.001 0.972
? 33.3(15/45) 80.0 52.4 39.3 ? ?
? 66.7(30/45) 80.0 59.4 45.4 ? ?
术后治疗 ? ? ? ? 0.233 0.629
? 19.6(10/51) 70.0 40.0 35.0 ? ?
? 80.4(41/51) 78.0 56.1 36.9 ? ?
胃切除范围 ? ? ? ? 2.421 0.298
? 胃近端切除 22.4(11/49) 72.7 50.9 38.2 ? ?
? 胃远端切除 51.0(25/49) 88.0 66.7 56.7 ? ?
? 全胃切除 26.5(13/49) 76.8 53.8 35.9 ? ?
手术根治度 ? ? ? ? 14.802 <0.001
? R0切除 71.4(35/49) 91.4 72.9 60.5 ? ?
? 姑息切除 28.6(14/49) 64.3 28.6 7.1 ? ?
侵犯脏器 ? ? ? ? 16.092 <0.001
? 32.0(16/50) 50.0 19.4 9.7 ? ?
? 68.0(34/50) 85.3 75.8 56.6 ? ?
肿瘤大小 ? ? ? ? 4.682 0.004
? ≥5.0 cm 43.8(21/48) 83.3 66.7 58.3 ? ?
? <5.0 cm 56.2(27/48) 82.1 73.7 49.9 ? ?
Ann Arbor分期 ? ? ? ? 9.323 0.029
? ⅠE期 41.5(22/53) 90.9 79.3 52.0 ? ?
? ⅡE期 37.7(20/53) 75.0 44.0 37.7 ? ?
? ⅢE期 1.9(1/53) - - - ? ?
? ⅣE期 18.9(10/53) 40.0 30.0 20.0 ? ?
组织分型 ? ? ? ? 12.872 0.006
? MALT 64.2(34/53) 82.4 76.0 58.8 ? ?
? HL 7.5(4/53) 60.0 33.3 15.7 ? ?
? DLBCL 22.6(12/53) 58.3 33.3 25.0 ? ?
? 淋巴浆细胞型淋巴瘤 5.6(3/53) - - - ? ?
表3 PGL预后影响因素的多因素分析
图1 手术根治度对原发性胃淋巴瘤生存预后的影响
图2 组织分型对原发性胃淋巴瘤生存预后的影响
图3 Ann Arbor分期对原发性胃淋巴瘤生存预后的影响
表4 MALT与DLBCL患者的预后影响相关性因素分析
病例资料 MALT[%(例/例)] 5年生存率(%) χ2 P DLBCL[%(例/例)] 5年生存率(%) χ2 P
性别 ? ? 4.800 0.028 ? ? 2.088 0.148
? 67.6(23/34) 39.8 ? ? 50.0(6/12) 0.0 ? ?
? 32.4(11/34) 77.9 ? ? 50.0(6/12) 33.3 ? ?
年龄 ? ? 2.559 0.110 ? ? 0.102 0.749
? ≥60岁 38.2(13/34) 69.2 ? ? 75.0(9/12) 22.2 ? ?
? <60岁 61.8(21/34) 85.7 ? ? 25.0(3/12) - ? ?
肿瘤位置 ? ? 0.055 0.997 ? ? 3.083 0.379
? 上、上中 32.4(11/34) 49.1 ? ? 25.0(3/12) - ? ?
? 中、中下 23.5(8/34) 40.0 ? ? 16.7(2/12) - ? ?
? 下部 35.3(12/34) 62.5 ? ? 41.6(5/12) 20.0 ? ?
? 全胃 8.8(3/34) - ? ? 16.7(2/12) - ? ?
既往胃肠道疾病史 ? ? 0.169 0.681 ? ? 8.659 0.003
? 32.4(11/34) 56.1 ? ? 16.7(2/12) - ? ?
? 67.6(23/34) 59.5 ? ? 83.3(10/12) 30.0 ? ?
淋巴管瘤栓 ? ? 0.431 0.511 ? ? 1.647 0.199
? 37.9(11/29) 40.9 ? ? 30.0(3/10) - ? ?
? 62.1(18/29) 70.5 ? ? 70.0(7/10) 14.3 ? ?
术后治疗 ? ? 1.038 0.308 ? ? 0.422 0.516
? 21.9(7/32) 85.7 ? ? 25.0(3/12) - ? ?
? 78.1(25/32) 53.6 ? ? 75.0(9/12) 22.2 ? ?
胃切除范围 ? ? 3.786 0.151 ? ? 0.767 0.681
? 胃近端切除 29.0(9/31) 38.9 ? ? 18.2(2/11) - ? ?
? 胃远端切除 51.6(16/31) 77.3 ? ? 36.4(4/11) 25 ? ?
? 全胃切除 19.4(6/31) 30.0 ? ? 45.4(5/11) 20 ? ?
手术根治度 ? ? 18.189 0.000 ? ? 1.054 0.305
? R0切除 74.2(23/31) 77.7 ? ? 63.6(7/11) 28.6 ? ?
? 姑息切除 25.8(8/31) 12.5 ? ? 36.4(4/11) 0.00 ? ?
侵犯脏器 ? ? 17.455 <0.001 ? ? 0.232 0.630
? 24.2(8/33) 0.00 ? ? 45.4(5/11) 0.00 ? ?
? 75.8(25/33) 70.8 ? ? 54.6(6/11) 33.3 ? ?
肿瘤大小 ? ? 0.893 0.345 ? ? 0.325 0.569
? ≥5.0 cm 44.4(12/27) 48.6 ? ? 80.0(8/10) 12.5 ? ?
? <5.0 cm 55.6(15/27) 59.8 ? ? 20.0(2/10) - ? ?
Ann Arbor分期 ? ? 14.252 0.003 ? ? 0.089 0.766
? ⅠE期 52.9(18/34) 67.6 ? ? 16.7(2/12) - ? ?
? ⅡE期 23.5(8/34) 60.6 ? ? 83.3(10/12) 37.7 ? ?
? ⅢE期 2.9(1/34) - ? ? 0(0/12) - ? ?
? ⅣE期 20.6(7/34) 14.3 ? ? 0(0/12) - ? ?
[1]
Hwang JP, Lim I, Byun BH, et al. Prognostic value of SUVmax measured by pretreatment 18F-FDG PET/CT in patients with primary gastric lymphoma [J]. Nucl Med Commun, 2016, 37(12): 1267-1272.
[2]
Al-Akwaa AM, Siddiqui N, Al-Mofleh IA. Primary gastric lymphoma [J]. World J Gastroenterol, 2004, 10(1): 5-11.
[3]
D′Amore F, Christensen BE, Thorling K, et al. Incidence, presenting features and prognosis of low-grade B-cell non-Hodgkin′s lymphomas. Population-based data from a Danish lymphoma registry [J]. Leuk Lymphoma, 1993, 12(1-2): 69-77.
[4]
Koch P, Probst A, Berdel WE, et al. Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96) [J]. J Clin Oncol, 2005, 23(28): 7050-7059.
[5]
Dawson IM, Cornes JS, Morson BC. Primary malignant lymphoid tumours of the intestinal tract. Report of 37 cases with a study of factors influencing prognosis [J]. Br J Surg, 1961, 49: 80-89.
[6]
Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms [J]. 2016, 127(20): 2375-2390.
[7]
Kong SH, Kim MA, Park DJ, et al. Clinicopathologic features of surgically resected primary gastric lymphoma [J]. World J Gastroenterol, 2004, 10(8): 1103-1109.
[8]
Zullo A, Hassan C, Andriani A, et al. Primary low-grade and high-grade gastric MALT-lymphoma presentation [J]. J Clin Gastroenterol, 2010, 44(5): 340-344.
[9]
Vanis N, Mesihovic R, Ibricevic L, et al. Predictive value of endoscopic ultrasound in diagnosis and staging of primary gastric lymphoma [J]. Coll Antropol, 2013, 37 Suppl 1: 291-297.
[10]
Schaefer NG, Hany TF, Taverna C, et al. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT? [J]. Radiology, 2004, 232(3): 823-829.
[11]
Zukerberg LR, Ferry JA, Southern JF, et al. Lymphoid infiltrates of the stomach. Evaluation of histologic criteria for the diagnosis of low-gradegastric lymphoma on endoscopic biopsy specimens [J]. Am J Surg Pathol, 1990, 14(12): 1087-1099.
[12]
Koh YW, Park C, Yoon DH, et al. Prognostic significance of COX-2expression and correlation with Bcl-2 and VEGF expression, microvessel density, and clinical variables in classical Hodgkin lymphoma [J]. Am J Surg Pathol, 2013, 37(8): 1242-1251.
[13]
Wang YG, Zhao LY, Liu CQ, et al. Clinical characteristics and prognostic factors of primary gastric lymphoma: A retrospective study with 165 cases [J]. Medicine (Baltimore), 2016, 95(31): e4250.
[14]
He M, Gao L, Zhang S, et al. Prognostic significance of miR-34a and its target proteins of FOXP1, p53, and BCL2 in gastric MALT lymphoma and DLBCL [J]. Gastric Cancer, 2014, 17(3): 431-441.
[15]
Bairey O, Shacham-Abulafia A, Shpilberg O, et al. Serum albumin level at diagnosis of diffuse large B-cell lymphoma: an important simple prognostic factor [J]. Hematol Oncol, 2016, 34(4): 184-192.
[16]
Lim EL, Trinh DL, Scott DW, et al. Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients [J]. Genome Biol, 2015, 16: 18.
[17]
Zheng Z, Li X, Zhu Y, et al. Prognostic significance of miRNA in patients with diffuse large B-cell lymphoma: a meta-analysis [J]. Cell Physiol Biochem, 2016, 39(5): 1891-1904.
[18]
Sbitti Y, Ismaili N, Bensouda Y, et al. Management of stage one and two-E gastric large B-cell lymphoma: chemotherapy alone or surgery followed by chemotherapy? [J]. J Hematol Oncol, 2010, 3: 23.
[19]
Selcukbiricik F, Tural D, Elicin O, et al. Primary gastric lymphoma: conservative treatment modality is not inferior to surgery for early-stage disease [J]. ISRN Oncol, 2012, 2012: 951816.
[20]
Ferreri AJM, Cordio S, Paro S, et al. Therapeutic Management of Stage I–II High-Grade Primary Gastric Lymphomas [J]. Oncology, 1999, 56(4): 274-282.
[21]
Ge Z, Liu Z, Hu X. Anatomic distribution, clinical features, and survival data of 87 cases primary gastrointestinal lymphoma [J]. World J Surg Oncol, 2016, 14: 85.
[22]
Yoon SS, Coit DG, Portlock CS, et al. The diminishing role of surgery in the treatment of gastric lymphoma [J]. Ann Surg, 2004, 240(1): 28-37.
[23]
张浩然,翟云芝,楼建军, 等. 非霍奇金淋巴瘤患者血清β2-微球蛋白和CA125检测的意义[J]. 中国当代医药, 2014, 21(23): 51-53.
[24]
Raderer M, Wohrer S, Kiesewetter B, et al. Antibiotic treatment as sole management of Helicobacter pylori-negative gastric MALT lymphoma: a single center experience with prolonged follow-up [J]. Ann Hematol, 2015, 94(6): 969-973.
[1] 杨水华, 何桂丹, 覃桂灿, 梁蒙凤, 罗艳合, 李雪芹, 唐娟松. 胎儿孤立性完全型肺静脉异位引流的超声心动图特征及高分辨率血流联合时间-空间相关成像的应用[J]. 中华医学超声杂志(电子版), 2023, 20(10): 1061-1067.
[2] 杨倩, 李翠芳, 张婉秋. 原发性肝癌自发性破裂出血急诊TACE术后的近远期预后及影响因素分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 33-36.
[3] 栗艳松, 冯会敏, 刘明超, 刘泽鹏, 姜秋霞. STIP1在三阴性乳腺癌组织中的表达及临床意义研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 52-56.
[4] 彭旭, 邵永孚, 李铎, 邹瑞, 邢贞明. 结肠肝曲癌的诊断和外科治疗[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 108-110.
[5] 马伟强, 马斌林, 吴中语, 张莹. microRNA在三阴性乳腺癌进展中发挥的作用[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 111-114.
[6] 陈垚, 徐伯群, 高志慧. 改良式中间上入路根治术治疗甲状腺癌的有效性安全性研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 619-622.
[7] 李永胜, 孙家和, 郭书伟, 卢义康, 刘洪洲. 高龄结直肠癌患者根治术后短期并发症及其影响因素[J]. 中华临床医师杂志(电子版), 2023, 17(9): 962-967.
[8] 袁媛, 赵良平, 刘智慧, 张丽萍, 谭丽梅, 閤梦琴. 子宫内膜癌组织中miR-25-3p、PTEN的表达及与病理参数的关系[J]. 中华临床医师杂志(电子版), 2023, 17(9): 1016-1020.
[9] 王军, 刘鲲鹏, 姚兰, 张华, 魏越, 索利斌, 陈骏, 苗成利, 罗成华. 腹膜后肿瘤切除术中大量输血患者的麻醉管理特点与分析[J]. 中华临床医师杂志(电子版), 2023, 17(08): 844-849.
[10] 陆志峰, 周佳佳, 梁舒. 虚拟现实技术在治疗弱视中的临床应用研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(08): 891-895.
[11] 李田, 徐洪, 刘和亮. 尘肺病的相关研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(08): 900-905.
[12] 岳瑞雪, 孔令欣, 郝鑫, 杨进强, 韩猛, 崔国忠, 王建军, 张志生, 孔凡庭, 张维, 何文博, 李现桥, 周新平, 徐东宏, 胡崇珠. 乳腺癌HER2蛋白表达水平预测新辅助治疗疗效的真实世界研究[J]. 中华临床医师杂志(电子版), 2023, 17(07): 765-770.
[13] 索利斌, 刘鲲鹏, 姚兰, 张华, 魏越, 王军, 陈骏, 苗成利, 罗成华. 原发性腹膜后副神经节瘤切除术麻醉管理的特点和分析[J]. 中华临床医师杂志(电子版), 2023, 17(07): 771-776.
[14] 周婷, 孙培培, 张二明, 安欣华, 向平超. 北京市石景山区40岁及以上居民慢性阻塞性肺疾病诊断现状调查[J]. 中华临床医师杂志(电子版), 2023, 17(07): 790-797.
[15] 符梅沙, 周玉华, 李慧, 薛春颜. 淋巴细胞免疫治疗对复发性流产患者外周血T淋巴细胞亚群分布与PD1/PD-L1表达的影响及意义[J]. 中华临床医师杂志(电子版), 2023, 17(06): 726-730.
阅读次数
全文


摘要